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Abstract 
If metastatic prostate cancer gets resistant to antiandrogen therapy, there are few treatment 
options, because prostate cancer is not very sensitive to cytostatic agents. Temozolomide 
(TMZ) as an orally applicable chemotherapeutic substance has been proven to be effective 
and well tolerated with occasional moderate toxicity especially for brain tumors and an ap-
plication to prostate cancer cells seemed to be promising. Unfortunately, TMZ was ineffi-
cient in the treatment of symptomatic progressive hormone-refractory prostate cancer 
(HRPC). The reasons could be a low sensitivity against TMZ the short plasma half-life of 
TMZ, non-adapted application regimens and additionally, the aneuploid DNA content of 
prostate cancer cells suggesting different sensitivity against therapeutical interventions e.g. 
radiation therapy or chemotherapy. Considerations to improve this unsatisfying situation 
resulted in the realization of higher local TMZ concentrations, sufficient to kill cells regard-
less of intrinsic cellular sensitivity and cell DNA-index. Therefore, we reformulated the TMZ 
by ligation to a peptide-based carrier system called TMZ-BioShuttle for intervention. The 
modular-composed carrier consists of a transmembrane transporter (CPP), connected to a 
nuclear localization sequence (NLS) cleavably-bound, which in turn was coupled with TMZ. 
The NLS-sequence allows an active delivery of the TMZ into the cell nucleus after trans-
membrane passage of the TMZ-BioShuttle and intra-cytoplasm enzymatic cleavage and 
separation from the CPP. This TMZ-BioShuttle could contribute to improve therapeutic 
options exemplified by the hormone refractory prostate cancer. The next step was to syl-
logize a qualified method monitoring cell toxic effects in a high sensitivity under considera-
tion of the ploidy status. The high-resolution flow cytometric analysis showed to be an ap-
propriate system for a better detection and distinction of several cell populations dependent 
on their different DNA-indices as well as changes in proliferation of cell populations after 
chemotherapeutical treatment. 
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Introduction 
Prostate cancer (PCa) is the most common solid 
tumor in men. In 2007, there will be approximately 
220.000 men diagnosed with prostate cancer in the 
U.S. [1]. The annual incidence of the male population 
in West-Europe and the U.S.A averages approxi-
mately 88 per 100.000 men [2]. As the wide range of 
the PCa’s aggressiveness shows: while some patients 
are being able to live symptom-free and without any 
treatment for many years, there are aggressive forms 
with rapid growth and early metastatic spreading. 
The current therapeutic options in the treatment of 
PCa are: i) Radical excision of prostate and seminal 
vesicles [3, 4]. ii) Percutaneous radiation therapy with 
high energetic photons (6-23 MeV) [5, 6]. iii) Intersti-
tial radiation therapy with temporarily or permanent 
radioactive implants (brachytherapy) [7]. iv) The 
standard initial systemic therapy for locally advanced 
or metastatic disease is hormonal or androgen depri-
vation therapy (ADT) that may be performed by bi-
lateral orchiectomy or pharmaceutical means. The 
androgen-sensitive period in patients with metastatic 
disease lasts a median of 14–30 months [8]. v) Che-
motherapy for hormone refractory prostate cancer 
(HRPC) is possible using mitoxantrone plus predni-
sone [9] or with taxane-containing agents [10]. Despite 
manifold combined therapeutic approaches for a 
successful HRPC control in the past, metastatic AIPC 
and HRPC is difficult to treat [11-18]. Unfortunately, 
all current therapeutic options for patients with HRPC 
turned out to be poorly effective and chemotherapy 
had low response rates with median survivals of up to 
only 12 months [14]. Therefore, chemotherapy has not 
traditionally been offered to patients with HRPC as a 
routine treatment due to its treatment-related toxicity 
and poor response [19]. Despite initially encouraging 
results of tumor growth control were reported in 
other tumor types than brain tumors [20], the results 
of a phase II study of TMZ in PCa have been dis-
couraging [21]. One of the reasons for this could be 
the presence of aneuploid cell fractions, which offers a 
broad spectrum of cells from highly sensitive up to 
therapy resistant [22]. In addition, the therapy resis-
tant cell fraction gains a selective advantage after 
therapeutic intervention. The DU 145 cell line, pre-
senting a cellular heterogeneity, suggests behaviour’s 
similarity to advanced HRPC tumors. As demon-
strated by karyotypic analyses DU 145 show an ane-
uploid human karyotype with a modal chromosome 
number of 64. Marker chromosomes like translocated 
Y chromosome, metacentric minute chromosomes 
and three large acrocentic chromosomes have been 
identified [23, 24] which in their entirety can be re-
sponsible for the constricted sensitivity against alky-
lating agents.   
It is clear that effort is necessary to search for 
new forms of treatment modalities like drug delivery 
and targeting systems realizing high local TMZ con-
centrations in the nuclei of target cells. To eradicate 
the target cells, without considering the HRPC cells 
resistance against therapeutic interventions it is nec-
essary to find convenient methods which allow the 
monitoring of the therapy progress and success at the 
cellular level. Flow cytometric analysis should be able 
to detect several cell populations dependent on their 
different DNA-indices, which are corresponding to 
different amount in chromosome numbers. By this 
method, the genetic integrity and stability can be 
analyzed [25]. 
 
Materials & methods 
Cell culture 
The hormone refractory adherent prostate cancer 
cell line DU 145 [24] was cultivated and maintained in 
RPMI cell medium (Gibco, Germany) supplemented 
with 5% fetal calf serum and 4 mM glutamine (Bio-
chrome, Germany) at 37°C in 5% CO2 atmosphere.  
Chemical procedures 
The syntheses of the investigated peptide-based 
functional modules like the cell penetrating peptide 
(CPP) and the nuclear localization sequence (NLS) as 
well as the syntheses of tetracy-
clo-[5.4.21,7.O2,6.O8,11]3,5-dioxo-4-aza-9,12-tridecadien 
acting dienophile and the tetrazoline-derivatization of 
the active compound temozolomide to 
(TMZ-tetrazine diene) (Table 2, left column), and in 
the end, the both ligation procedures, firstly the liga-
tion of the dienophile-NLS module (Table 1, upper 
row) with cell penetrating peptide (CPP) (Table 1, 
lower row) by a reversible disulfide-bridge formation, 
and secondly, the compounds for the ligation in virtue 
to the Diels-Alder-Reaction with inverse elec-
tron-demand extensive described by Braun [26] and 
Pipkorn [27] are illustrated in Table 2. 
All reactions and procedures were carried out 
under normal atmosphere conditions. The Figure 1 
exhibits the constitutional formula of investigated 
active TMZ-NLS component.  
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Table 1  Schematic ligation pattern of the K(TcT)-NLS-Cys & CPP-Cys modules by disulfide bridge formation. Itemized 
modules of the investigated TMZ-BioShuttle. The upper line shows the chemical structure of the tetracy-
clo-[5.4.2
1,7.O
2,6.O
8,11]3,5-dioxo-4-aza-9,12-tridecadien (TcT) acting as dienophile compound in the DARinv. It is connected 
via the ε-amino-coupling of the lysine spacer to the nuclear address sequence (NLS). At the right site of the table the CPP 
module in the single letter code mode is represented. In the upper line the corresponding module in the single code mode 
is represented. 
 
Table 2  Middle and right part of the table represents the dienophile-educt for the DARinv: K(TcT)-NLS-S
∩S-CPP and the 
TMZ tetrazine spacer derivatized acts as a diene compound as a cargo (left column). 
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Figure 1  Constitutional formula of the investigated TMZ-BioShuttle 
 
Cell Cycle and Cell Death Analysis 
The effects on the cell viability and the cell cycle 
distribution were determined by DNA flow cytome-
try.  
Flow cytometric analyses were performed using 
a PAS II flow cytometer (Partec, Munster/Germany) 
equipped with mercury lamp 100 W and filter com-
bination for 2, 4-diamidino-2-phenylindole (DAPI) 
stained single cells. From native sampled probes the 
cells were isolated with 2.1% citric acid/ 0.5% Tween 
20 according to the method for high resolution DNA 
and cell cycle analyses [28] at room temperature with 
slightly shaking. Phosphate buffer (7.2g Na2HPO4 × 
2H2O in 100ml H2O dist.) pH 8.0 containing 2, 
4-diamidino-2-phenylindole (DAPI) for staining the 
cell suspension was performed. Each histogram 
represents 30.000 cells for measuring DNA-index and 
cell cycle. For histogram analysis we used the Multi-
cycle program (Phoenix Flow Systems, San Diego, 
CA). 
Human lymphocyte nuclei from healthy donors 
were used as internal standard for determination the 
diploid cell population. The mean coefficient of varia-
tion (CV) of the diploid lymphocytes was 0.8 - 1.0.  
Cell viability and apoptotic cells were assessed 
by flow cytometry with propidium iodide 
(PI)-method. For detection of apoptotic cells and vi-
ability a FACS Calibur flow cytometer (Becton Dick-
inson Cytometry Systems, San Jose, CA) was used 
with filter combinations for propidium iodide. For 
analyses and calculations the Cellquest program 
(Becton Dickinson Cytometry Systems, San Jose, CA) 
was used. Each histogram represents 10.000 cells. Af-
ter preparation according to Nicoletti with modifica-
tions [29, 30] measurements were acquired in Fl-2 in 
logarithmic mode and calculated by setting gates over 
the first three decades to detect apoptotic cells. The 
effect of the used solvent acetonitrile on the viability 
of lymphocytes was without pathological findings. 
Preparation of short term lymphocytes 
Human lymphocytes were isolated from 30ml 
native venous blood from a healthy donor by a lym-
phocyte preparation with LymphoprepTM gradient 
(AXIS-Shield PoC AS, Norway) under sterile condi-
tions. A short term culture was established with lym-
phocytes using RPMI 1640 medium, containing 10% 
foetal calf serum and Phytohemagglutinin (PHA-P) 
(5mg/ml) in phosphate buffer solution PBS (Sigma, 
Germany) at 37°C and 5% CO2 for 144 hours. 
Treatment of lymphocytes was followed by 
identical procedures according to the DU 145 cells. 
The suspension culture was harvested by centrifuga-
tion at 800rpm for 10min, rinsed in PBS and marked 
with propidium iodide (PI) before measurement in a 
FACS-calibur flow cytometer (Becton & Dickinson, 
Germany) equipped with a 488nm argon laser and 
emission filter combinations for red fluorescence 
(610nm) using the Cell Quest acquisition and analyses 
software (Becton & Dickinson, Germany). For analysis 
a minimum of 10.000 cells were counted and the re-
sults were presented as histograms in logarith-
mic-modus. The specific fluorescence intensity was 
calculated as the ratio of the geometric mean fluores-
cence values obtained with the specific PI-uptake. 
Results 
The aims of the study were:  
1. to achieve a rapid and high local concentration 
and an accumulation of TMZ derivative within the 
cell nuclei using the TMZ-BioShuttle as delivery and 
targeting system.  Int. J. Med. Sci. 2009, 6 
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2. the presentation, distinction and evaluation of 
the cell cycle behaviour of aneuploid DU 145 prostate 
cancer cells after treatment with TMZ alone and with 
its TMZ-BioShuttle derivative.  
Control DU 145 cells form a continuous 
monolayer, while treated DU 145 cells show loss of 
adhesion primarily in the TMZ-BioShuttle treated 
cells combined with spread and attached to the 
well-plate. Whereas in the TMZ treated cells, the cell 
closeness was declined and accompanied with an in-
crease of amount of dead cells in the supernatant. 
Using the flow cytometry technique not only a 
differentiation in the cell cycle state of DU 145 cells 
but also a schedule line of the diploid (red) and an 
aneuploid (blue) DNA content of the DU 145 cells is 
demonstrated as shown in Figure 2 and table 3 A, 
graphically visualized in 3B.  
 
 
 
 
 
 
Figure 2  The figure shows the cell cycle distribution of DU 145 cells: In the left part of the figure the plot of the untreated 
control is demonstrated, the middle and the right plot show the cell cycle distribution 144 h after treatment with 
TMZ-BioShuttle and TMZ respectively. The prostate cancer cell line exhibits two cell fractions: a diploid (DNA-index of 
1.0)[red coloured] and an aneuploid fraction (DNA-index 1.1)[blue coloured], close to the diploid. The G1 and the G2M 
peaks show a diploid and an aneuploid DNA content respectively. S-phase: After TMZ treatment (right plot) the cell number 
of the aneuploid cells is 10% higher (59 %) compared to aneuploid S-Phase cells in the TMZ-BioShuttle treated probe (middle 
plot). This in turn was 1.8 fold increased (49 %) compared to the corresponding cell fraction of the control (27 %). The 
relative amount of the diploid cell fraction differs from the aneuploid fraction: The control shows 35 % diploid cells. The 
aneuploid fractions reveal decreased amounts 15% (TMZ-BioShuttle) and 3% (TMZ). G2/M phase: The cell cycle behaviour 
of both cell fractions, the diploid and the aneuploid, show partly opposing effects. In comparison to the control which shows 
identical percentage of the diploid and the aneuploid cells, the TMZ and the TMZ-BioShuttle treated probes display an 
increased diploid cell fraction in which the TMZ-BioShuttle probe shows the highest cell contingent. The fraction of ane-
uploid cells is reduced to 11% whereas the diploid part is increased to 28% in the TMZ-BioShuttle treated probe. The 
amount of cells in the G2/M phase is increased in a similar ratio of 25 % diploid and 24 % aneuploid cells in the TMZ probe. 
G1-phase: The comparison of the amount of aneuploid and diploid cells in the G1 phase shows a ratio of 49 % and 54%. The 
cells in the G1 phase of the TMZ treated probe was increased to 73 % (diploid) and 57 % in the TMZ-BioShuttle probe. The 
aneuploid cell fractions exhibit an opposite result: the aneuploid cell fraction is decreased to 41% (TMZ-BioShuttle) and 17 
% (TMZ). Int. J. Med. Sci. 2009, 6 
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Table 3  The relative appointment [%] of the particular cell fractions of the cell cycle in DU 145 cells is listed in the table 
3A and vertical bar chart 3B. Diploid (red) and aneuploid (blue) DNA contents are demonstrated. The varying cell frac-
tion’s properties are clarified by connecting lines.  
 
 
 
 
The cell cycle distribution of the untreated con-
trol cells shows two different cell fractions harbouring 
a diploid (49%) and an aneuploid part (54%) in the G1 
phase. Both cell fractions have a rate of 19% in the 
G2/M phase respectively. The cell fraction in the S 
phase possesses a diploid / aneuploid ratio of 35% to 
27%.  
The cell cycle distribution of the diploid and 
aneuploid cell fractions after treatment with TMZ 
alone and with TMZ-BioShuttle shows different pat-
terns. The amount of the diploid cell fraction and of 
the aneuploid fraction is opposed in untreated cells 
compared with the cells in the G1 phase of the 
TMZ-BioShuttle and TMZ cell fractions (table 3A).  
In contrast to the untreated control cell fractions 
in the G1-phase, the diploid part of the 
TMZ-BioShuttle treated cells in the G1 phase is 
slightly increased to 57% whereas the aneuploid frac-
t i o n  i s  d e c r e a s e d  t o  4 1 % .  T h i s  d i f f e r e n t  b e h a v i o u r  
could be caused by an arrest of diploid cells in the G1 
phase, whereas the cells of the aneuploid fraction pass 
from the G1 into the S phase.  
This finding is confirmed by the investigation of 
DU 145 cells in the S phase: TMZ-BioShuttle treated 
cells show in the S phase cell fraction a decreased 
amount of diploid (15%) but an increased amount of 
aneuploid cells (49%). The increase of diploid cells to 
28% in the G2/M phase and a parallel decrease of the 
amount of aneuploid cells to 11% measured after 
TMZ-BioShuttle treatment exhibit a similar cell cycle 
behaviour of both cell fractions. This amount of dip-
loid cells suggests an arrest in the G2/M phase, while 
the aneuploid cell fraction runs through this phase 
into the S phase. 
The DU 145 cells treated with TMZ show dif-
ferent cell cycle behaviour and a different 
DNA-index-dependant sensitivity. The treatment re-
sults in increasing amounts of cells of the diploid Int. J. Med. Sci. 2009, 6 
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(25%) and of the aneuploid cell (24%) fraction in the 
G2/M phase.  
The amount of diploid TMZ treated cells in-
creased to 73 % (!) featuring an arrest of diploid cells 
in the G1 phases in contrast to the aneuploid fraction 
which is reduced to 17%. This could be a hint for a 
block by TMZ-sensitivity in the G1 phase. The ane-
uploid cell fraction however proves to be insensitive 
against TMZ and the G1 phase seems to be reduced 
because the cells reach the S phase as shown in the 
measurements. The diploid cells in the S phase are 
reduced to 3%, whereas the part of aneuploid cells 
exhibits an extreme increase to 59%! 
Moreover, this strong increase of the aneuploid 
cell fraction in the S phase could be an evidence for a 
cell cycle block in the S phase.  
Lymphocytes treatment 
Undesired effects of the TMZ on peripheric 
lymphocytes of patients often show a leukopenia like 
hemogram. A reformulation of TMZ should circum-
vent these adverse reactions, limiting the therapeutic 
outcome. 
Under the aspect of a potential future use of the 
TMZ-BioShuttle in patients, we investigated fresh 
human lymphocytes for survival of the treatment in 
the used concentrations and with our solvent. The 
life/dead cells data are depicted in Figure 3.  
For studies cells were seeded at a density of 1.8 × 
106 cells/ml. After incubation with TMZ and 
TMZ-BioShuttle in a final concentration of 50µM re-
spectively, DU 145 cells were incubated and meas-
ured after 48 hours. 
 
 
Figure 3  Histograms of lymphocytes of one healthy proband is represented exemplarily. The histogram shows in a 
log-mode the relative fluorescence intensities of human lymphocytes marked with PI. By setting the gate M1 apoptotic cells 
are marked, morphologically intact cells with intact DNA content could be observed with higher relative fluorescence 
intensity in the gate M2.  
 
The observation of effects of the TMZ molecule 
and its TMZ-BioShuttle respectively in blood of four 
healthy test persons permits an estimation of the tox-
icity. 72 hours after treatment the ratio of the fraction 
of dead cells was nearly constant at a median of 4.7 % 
and 4.5 % in the untreated control as well as in the 
TMZ-BioShuttle treated cells. The average of the TMZ 
treated lymphocytes was increased to 6.2 %. Six days 
after treatment the amount of dead cells was in-
creased but constant on the untreated lymphocytes 
and in the TMZ-BioShuttle at 10.2 % whereas the 
TMZ-probe showed 14.2 % dead cells.  
It turned out that high-resolution flow cytomet-
ric measurements are suitable for monitoring the 
therapeutic success at the cellular level.  
The achievement of relevant high local concen-
trations of therapeutic substances at the side of action, 
like in the nuclei of tumor cells was realized using 
delivery systems like the modularly composed pep-
tide-based BioShuttle which brings chemical agents 
like TMZ into cells and in a second step into the cell 
nuclei. Regardless the cell’s aneuploid state, respon-Int. J. Med. Sci. 2009, 6 
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sible for the restricted pharmacological effects of 
chemotherapeutic agents, the local concentration is 
sufficient to overcome the intractability for cell killing 
under protection non-affected cells and the sur-
rounding healthy tissue. 
Aneuploidy is considered as the primary cause 
of the high rates and wide ranges of drug resistance in 
cancer cells. 
Discussion 
The outcome after chemotherapy still shows 
poor results with respect to overall survival in the 
treatment of advanced HRPC [31-33]. The resistance 
against therapeutic interventions is not completely 
understood, but various factors may be considered: 
The behaviour of this form of PCas could be ex-
plained by either the loss of the homoeostasis’s con-
trols between cell proliferation and programmed cell 
death (apoptosis) [34, 35]. Tumorigenesis and pro-
gression are independent processes initiated and 
boosted by aberrant activation of cell cycle activating 
pathways but also by the inactivation of cell death 
associated signals resulting in the loss of the prolif-
eration control and in the augmented resistance 
against apoptosis respectively [36]. Additionally re-
cent data indicate that the inhibition of apoptosis is 
not associated with the transformation process to ma-
lign cells [37]. But affected cells show a prolonged 
cellular survival time and rate [38] compared with 
normal tissue. Both events can be detected in highly 
aggressive prostate cancer resistant to chemo- or /and 
radiation therapy. Anti-angiogenesis strategies 
avoiding the disappointing results are discussed [39]. 
The increasing understanding of molecular mecha-
nisms and of the complex regulatory cellular network 
gives reason for several molecular approaches with 
high sensitivity and specificity for successful thera-
peutic intervention with lower side effects. Several 
approaches, like siRNA [40], Human-Antigen R 
(HuR) [41], [A+U]-rich element (ARE) [42], 
opener/closer mediated [43, 44] gene regulation [45] 
could be promising strategic approaches [46] in the 
treatment of HRPC.  
But we are at the beginning and up to the clinical 
practice large scores of hurdles must to be taken. Until 
then, it must be resorted to reliable currently available 
drugs like the alkylating agent temozolomide (TMZ). 
The TMZ new-formulation with the focus enhancing 
the TMZ transport into the almost untreatable 
glioblastoma multiforme (GBM) is well documented 
and revealed higher pharmacological effect as TMZ 
alone.[47] Recent data indicate, compared to different 
primary glioblastoma cells, a lower sensitivity of DU 
145 prostate cancer cells against TMZ treatment 
whereas all probes TMZ-BioShuttle treated showed 
dramatic cell cycle responses and diminished cell vi-
ability. [48]  
The increased amount of diploid cells in the G1 
phase after TMZ treatment suggests a cell trapping of 
the diploid cells in the G2/M phase. It is well docu-
mented that both cell cycle phase points G1 and 
G2/M represent check points for control and repair 
maintaining the genomic DNA-integrity.[49-51] 
Therefore among other things, both phases are char-
acterized by low sensitivity against DNA-damaging 
interventions like exposition to ionizing radiation and 
after chemotherapeutic alkylation [52], whereas the 
latter part of the S phase is highly sensitive against 
DNA-damaging effectors.[53] Presumably the block 
of the diploid cell fraction of the DU 145 cells in the G1 
phase allows the DNA-repair and subsequently the 
re-entry in the cell cycle. Therefore these cells turn out 
to be refractory against TMZ as shown in the 
TMZ-based therapy of advanced CaP.  
In contrast to the described DNA fragmentation 
of glioma cells after TMZ treatment [54] the 
TMZ-BioShuttle treated glioma cells exhibited a de-
viant pattern: no comet formation indicating DNA 
single-strand breaks but cells swollen were ob-
served.[48] This results from a loss of plasma mem-
brane integrity which suggests nuclear chromatin 
decondenzation considered as necrosis biomarker.[55, 
56] The observation, that the TMZ and the 
TMZ-BioShuttle influence unequally the cell cycle 
behaviour of DU 145 prostate cancer cells could indi-
cate a mode of action different from the documented 
methylation of the O6 position of guanine in the ge-
nomic DNA [57]. 
It remains to speculate to which extent the ane-
uploidy state of the DU 145 cells could influence the 
pharmacological effect of the TMZ on the prolifera-
tion behaviour. Flow cytometric cell cycle studies ex-
hibit an enhanced fraction of S phase cells of the nu-
meric aberrant chromosomes harbouring cells. DU 
145 karyotype analyses show the threefold existence 
of the chromosome 8. The impact of alterations of 
chromosome 8 and the high-grade state of advanced 
prostate carcinoma is well documented and appears 
to be associated with poor prognosis [58]. We would 
like to emphasize that alterations of the chromosome 
8 indicate an early critical step in the prostate tu-
morigenesis [59]. C-myc is localized at chromosome 8 
[60] and its overrepresentation is associated with 
prostate cancer progression [61]. Due to the fact that 
prostate cancer is one of the leading causes of death in 
the industrialized world, the need of new approaches 
for control the CaP is the major goal in the current 
research.  Int. J. Med. Sci. 2009, 6 
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As the results show the DNA-cytometry proves 
to be a dedicated diagnostic tool in the cytopathology 
by measurements of the DNA-content in cells and 
tissues. Within the scope of the tumor diagnostics, 
objective and valid gradiations of the malignant po-
tential of cells of different tumors and inside of a tu-
mor (in process control) are possible. For the purpose 
of the malignant grading the extent of the 
DNA-aneuploidy must be quantified. Given the fact 
that different tumor identities present different sec-
ondary and tertiary aberrations of chromosomes 
during the tumor progression, the prognostic inter-
pretation of the DNA-distribution must be realized 
tumor-specifically. In case of CaP (early state) the 
DNA malignant grading allows relevant early thera-
peutic decisions. High resolution flow cytometry is an 
appropriate tool not restricted to the monitoring of the 
therapeutic effect. DNA aneuploidy, as determined 
with high-resolution flow cytometry, has been shown 
to be an excellent and independent predictor of cell 
survival [62]. 
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